GenomOncology has appointed David Lasecki as chief commercialization officer. In this position, Lasecki will lead the company's growth strategy by working with key stakeholders in the healthcare industry to promote the widespread adoption of precision medicine. Most recently, he served as president of CompanionDx Labs and additionally presided over the commercialization of CompanionDx's oncology-specific DNA sequencing and pharmacogenomics tests. Lasecki has also held a variety of sales and new business development roles with AmerisourceBergen's specialty group, the International Oncology Network.
Premaitha Health has appointed William Denman as executive director of its board of directors. Denman has worked at Premaitha for four years and most recently served as the company's chief medical officer. Previously, he was CMO at GE Healthcare. He also worked at Coviden and was responsible for strategic direction of medical affairs.
Molecular Diagnostics has appointed Lee McCracken to its board of directors. In 2014, McCracken was appointed CEO of Gensignia Life Sciences. Previously, he held positons as president and CEO of Pathwork Diagnostics. Before that, McCracken served as corporate head of business development at Prometheus Laboratories, senior vice president of pharma business development at Diversa (merged with Verenium), president and chief business officer of GenStar Therapeutics, and senior vice president of corporate development at CombiChem (acquired by DuPont Pharmaceuticals).
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.